Do Sandoz’ Q2 Results Indicate US Bottom Is In Sight?
Novartis Unit Raises Annual Guidance As Q2 ‘Outweighs Expectations’
Sandoz has been able to hike its previously flat full-year annual guidance following an upward trajectory for the company, especially in Europe and the US. One analyst pondered whether this suggested the “emergence of a bottom in the US generics sector” during the second half of the year.
You may also be interested in...
Following years of dedicated moves towards greater autonomy for Sandoz, the generics and biosimilars giant is to become a publicly traded, standalone firm via a 100% spin-off from parent Novartis. However, a substantial offer could still derail plans.
A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.
Fresenius Kabi is pressing on with its ‘Vision 2026’ strategic growth initiatives, with the company wrapping up its acquisition of Insud Pharma’s bio unit mAbxience. However, it remains “to some degree output constrained,” which looks set to continue to impact operations, amid staff shortages.